vs

Side-by-side financial comparison of Sight Sciences, Inc. (SGHT) and UNITED SECURITY BANCSHARES (UBFO). Click either name above to swap in a different company.

Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $13.5M, roughly 1.5× UNITED SECURITY BANCSHARES). UNITED SECURITY BANCSHARES runs the higher net margin — 25.2% vs -20.4%, a 45.6% gap on every dollar of revenue. On growth, UNITED SECURITY BANCSHARES posted the faster year-over-year revenue change (13.6% vs 6.9%). UNITED SECURITY BANCSHARES produced more free cash flow last quarter ($19.8M vs $-2.0M). Over the past eight quarters, UNITED SECURITY BANCSHARES's revenue compounded faster (3.0% CAGR vs 2.9%).

Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.

United Security Bancshares is a bank holding company headquartered in Fresno, California. It operates 11 branches.

SGHT vs UBFO — Head-to-Head

Bigger by revenue
SGHT
SGHT
1.5× larger
SGHT
$20.4M
$13.5M
UBFO
Growing faster (revenue YoY)
UBFO
UBFO
+6.7% gap
UBFO
13.6%
6.9%
SGHT
Higher net margin
UBFO
UBFO
45.6% more per $
UBFO
25.2%
-20.4%
SGHT
More free cash flow
UBFO
UBFO
$21.8M more FCF
UBFO
$19.8M
$-2.0M
SGHT
Faster 2-yr revenue CAGR
UBFO
UBFO
Annualised
UBFO
3.0%
2.9%
SGHT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SGHT
SGHT
UBFO
UBFO
Revenue
$20.4M
$13.5M
Net Profit
$-4.2M
$3.4M
Gross Margin
87.3%
Operating Margin
-18.0%
31.5%
Net Margin
-20.4%
25.2%
Revenue YoY
6.9%
13.6%
Net Profit YoY
64.9%
36.8%
EPS (diluted)
$-0.07
$0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SGHT
SGHT
UBFO
UBFO
Q4 25
$20.4M
$13.5M
Q3 25
$19.9M
$14.0M
Q2 25
$19.6M
$12.6M
Q1 25
$17.5M
$13.7M
Q4 24
$19.1M
$11.9M
Q3 24
$20.2M
$13.8M
Q2 24
$21.4M
$13.0M
Q1 24
$19.3M
$12.8M
Net Profit
SGHT
SGHT
UBFO
UBFO
Q4 25
$-4.2M
$3.4M
Q3 25
$-8.2M
$4.0M
Q2 25
$-11.9M
$2.2M
Q1 25
$-14.2M
$2.7M
Q4 24
$-11.8M
$2.5M
Q3 24
$-11.1M
$3.8M
Q2 24
$-12.3M
$4.3M
Q1 24
$-16.3M
$4.2M
Gross Margin
SGHT
SGHT
UBFO
UBFO
Q4 25
87.3%
Q3 25
86.4%
Q2 25
84.8%
Q1 25
86.2%
Q4 24
86.8%
Q3 24
83.9%
Q2 24
85.8%
Q1 24
85.5%
Operating Margin
SGHT
SGHT
UBFO
UBFO
Q4 25
-18.0%
31.5%
Q3 25
-39.7%
40.3%
Q2 25
-59.6%
24.0%
Q1 25
-79.2%
27.5%
Q4 24
-62.5%
27.5%
Q3 24
-55.7%
37.1%
Q2 24
-59.2%
46.4%
Q1 24
-76.4%
45.9%
Net Margin
SGHT
SGHT
UBFO
UBFO
Q4 25
-20.4%
25.2%
Q3 25
-41.0%
28.7%
Q2 25
-61.0%
17.2%
Q1 25
-80.8%
19.6%
Q4 24
-62.1%
20.9%
Q3 24
-54.9%
27.7%
Q2 24
-57.7%
33.0%
Q1 24
-84.4%
32.6%
EPS (diluted)
SGHT
SGHT
UBFO
UBFO
Q4 25
$-0.07
$0.18
Q3 25
$-0.16
$0.23
Q2 25
$-0.23
$0.13
Q1 25
$-0.28
$0.16
Q4 24
$-0.23
$0.14
Q3 24
$-0.22
$0.22
Q2 24
$-0.25
$0.25
Q1 24
$-0.33
$0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SGHT
SGHT
UBFO
UBFO
Cash + ST InvestmentsLiquidity on hand
$92.0M
$264.2M
Total DebtLower is stronger
$42.4M
Stockholders' EquityBook value
$63.9M
$139.7M
Total Assets
$115.3M
$1.2B
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SGHT
SGHT
UBFO
UBFO
Q4 25
$92.0M
$264.2M
Q3 25
$92.4M
$211.1M
Q2 25
$101.5M
$199.5M
Q1 25
$108.8M
$198.4M
Q4 24
$120.4M
$216.9M
Q3 24
$118.6M
$216.8M
Q2 24
$118.2M
$166.3M
Q1 24
$127.3M
$168.6M
Total Debt
SGHT
SGHT
UBFO
UBFO
Q4 25
$42.4M
Q3 25
$42.4M
Q2 25
$42.4M
Q1 25
$42.4M
Q4 24
$40.0M
Q3 24
$37.1M
Q2 24
$35.0M
Q1 24
$35.0M
Stockholders' Equity
SGHT
SGHT
UBFO
UBFO
Q4 25
$63.9M
$139.7M
Q3 25
$64.3M
$137.4M
Q2 25
$70.0M
$134.3M
Q1 25
$77.6M
$132.9M
Q4 24
$87.5M
$130.4M
Q3 24
$95.0M
$132.9M
Q2 24
$101.6M
$127.3M
Q1 24
$109.2M
$124.2M
Total Assets
SGHT
SGHT
UBFO
UBFO
Q4 25
$115.3M
$1.2B
Q3 25
$116.3M
$1.2B
Q2 25
$122.0M
$1.2B
Q1 25
$129.7M
$1.2B
Q4 24
$142.8M
$1.2B
Q3 24
$143.6M
$1.3B
Q2 24
$149.7M
$1.2B
Q1 24
$155.6M
$1.2B
Debt / Equity
SGHT
SGHT
UBFO
UBFO
Q4 25
0.66×
Q3 25
0.66×
Q2 25
0.61×
Q1 25
0.55×
Q4 24
0.46×
Q3 24
0.39×
Q2 24
0.34×
Q1 24
0.32×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SGHT
SGHT
UBFO
UBFO
Operating Cash FlowLast quarter
$-1.8M
$22.1M
Free Cash FlowOCF − Capex
$-2.0M
$19.8M
FCF MarginFCF / Revenue
-9.7%
146.0%
Capex IntensityCapex / Revenue
0.8%
16.8%
Cash ConversionOCF / Net Profit
6.46×
TTM Free Cash FlowTrailing 4 quarters
$36.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SGHT
SGHT
UBFO
UBFO
Q4 25
$-1.8M
$22.1M
Q3 25
$-8.7M
$7.0M
Q2 25
$-7.5M
$8.7M
Q1 25
$-11.6M
$3.0M
Q4 24
$-3.5M
$19.6M
Q3 24
$362.0K
$5.4M
Q2 24
$-9.5M
$2.3M
Q1 24
$-9.8M
$7.4M
Free Cash Flow
SGHT
SGHT
UBFO
UBFO
Q4 25
$-2.0M
$19.8M
Q3 25
$-8.9M
$6.1M
Q2 25
$-7.8M
$8.1M
Q1 25
$2.9M
Q4 24
$-3.6M
$18.6M
Q3 24
$311.0K
$5.3M
Q2 24
$-9.5M
$2.0M
Q1 24
$-9.9M
$7.0M
FCF Margin
SGHT
SGHT
UBFO
UBFO
Q4 25
-9.7%
146.0%
Q3 25
-44.7%
43.7%
Q2 25
-39.6%
64.3%
Q1 25
21.2%
Q4 24
-18.9%
156.0%
Q3 24
1.5%
38.1%
Q2 24
-44.7%
15.5%
Q1 24
-51.4%
54.8%
Capex Intensity
SGHT
SGHT
UBFO
UBFO
Q4 25
0.8%
16.8%
Q3 25
0.9%
6.0%
Q2 25
1.1%
4.6%
Q1 25
0.0%
0.9%
Q4 24
0.7%
8.7%
Q3 24
0.3%
0.7%
Q2 24
0.4%
2.2%
Q1 24
0.6%
3.6%
Cash Conversion
SGHT
SGHT
UBFO
UBFO
Q4 25
6.46×
Q3 25
1.73×
Q2 25
4.01×
Q1 25
1.13×
Q4 24
7.87×
Q3 24
1.40×
Q2 24
0.54×
Q1 24
1.79×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SGHT
SGHT

Surgical Glaucoma$19.7M96%
Other$724.0K4%

UBFO
UBFO

Segment breakdown not available.

Related Comparisons